Publications by authors named "Patrizia Perazzo"
Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist approved for the treatment of Crohn's disease (CD). Only limited real-life data on the long-term outcomes of CD patients treated with UST are available. This study assessed UST's long-term effectiveness and safety in a large population-based cohort of moderate to severe CD patients.
View Article and Find Full Text PDFAnxiety is the most prevalent mental health disorder among adults worldwide. Given its increased prevalence among migrants due to their marginalized position in the societies where they reside, psychometric evaluations of anxiety measures such as the Generalized Anxiety Disorder-7 (GAD-7) are needed for use with migrants. The present study is the first attempt to compare the structure of GAD-7 scores for (a) different Latino groups in the same country and (b) the same Latino group in two different countries.
View Article and Find Full Text PDFBackground: Vedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn's disease (CD). We assessed whether there are differences in treating UC vs CD with VDZ.
Research Design And Methods: Mayo score in UC and the Harvey-Bradshaw Index (HBI) in CD scored the clinical activity.
The present article proposes an extension of the concept of adverse childhood experiences (ACEs) to apply to crisis migration - where youth and families are fleeing armed conflicts, natural disasters, community violence, government repression, and other large-scale emergencies. We propose that adverse events occurring prior to, during, and following migration can be classified as crisis-migration-related ACEs, and that the developmental logic underlying ACEs can be extended to the new class of crisis-migration-related ACEs. Specifically, greater numbers, severity, and chronicity of crisis-migration-related ACEs would be expected to predict greater impairments in mental and physical health, poorer interpersonal relationships, and less job stability later on.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted to compare the efficacy and safety of four adalimumab (ADA) biosimilars in patients with inflammatory bowel disease (IBD) after they were switched from the original ADA for non-medical reasons.
- Out of 153 IBD patients, 81% maintained clinical remission during a 12-month follow-up, and there was no significant difference in outcomes among the four biosimilars.
- However, patients with ulcerative colitis (UC) experienced a higher loss of remission compared to those with Crohn's disease (CD), indicating that switching biosimilars in UC patients may require careful evaluation.
Article Synopsis
- The approval of adalimumab biosimilars has led to lower treatment costs for inflammatory bowel disease (IBD).
- A study compared the effectiveness and safety of the biosimilar GP2017 (Hyrimoz) to the original drug Humira in IBD patients in Italy.
- Results showed similar rates of clinical remission and good tolerance for both treatments, indicating that GP2017 is as effective and safe as its original counterpart.
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
Inflamm Bowel Dis
March 2023
Article Synopsis
- Adalimumab (ADA) biosimilars are more affordable options for treating inflammatory bowel disease (IBD), but data comparing their effectiveness and safety remains limited.* -
- A study analyzed 533 IBD patients in Italy, measuring clinical activity, remission induction, and safety across four ADA biosimilars (SB5, ABP501, GP2017, and MSB11022).* -
- Results showed high clinical remission rates (79.6% for new biologics and 81.0% for patients switched from the ADA originator) with low adverse events (6.7%), indicating similar efficacy and safety among the different biosimilars.*
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
Expert Opin Biol Ther
February 2022
Background: To compare the performances of Infliximab (IFX) biosimilar CT-P13 and SB2 in the treatment of Inflammatory Bowel Diseases (IBD) outpatients in Italy.
Research Design And Methods: Three hundred and eighty IBD outpatients were retrospectively evaluated. The primary endpoint was to compare the two IFX biosimilars in terms of reaching and maintenance of remission at any timepoint.